• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

DEFERASIROX Drug Record

  • Summary
  • Interactions
  • Claims
  • DEFERASIROX chembl:CHEMBL550348 Approved

    Alternate Names:

    DEFERASIROX
    JADENU SPRINKLE
    JADENU
    EXJADE
    ICL670
    ICL-670
    ICL670A
    ICL-670A
    ICL 670
    ICL 670A
    DEFERASIROXUM
    drugbank:01609
    rxcui:614373
    pubchem.compound:5493381
    chemidplus:201530-41-8
    chembl:CHEMBL550348

    Drug Info:

    (0 More Sources)

    Publications:

    Allegra S et al., 2019, The effect of vitamin D pathway genes and deferasirox pharmacogenetics on liver iron in thalassaemia major patients., Pharmacogenomics J
    Marano M et al., 2016, Deferasirox-induced serious adverse reaction in a pediatric patient: pharmacokinetic and pharmacogenetic analysis., Eur J Clin Pharmacol
    Cusato J et al., 2015, Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness., Pharmacogenomics J
    Allegra S et al., 2016, Deferasirox AUC efficacy cutoff and role of pharmacogenetics., Eur J Clin Pharmacol
    Allegra S et al., 2018, Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes., Pharmacogenomics J
    Allegra S et al., 2018, Effect of pharmacogenetic markers of vitamin D pathway on deferasirox pharmacokinetics in children., Pharmacogenet Genomics
    Allegra S et al., 2017, Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients., Pharmacogenomics
    Cusato J et al., 2016, Role of pharmacogenetics on deferasirox AUC and efficacy., Pharmacogenomics
  • DEFERASIROX   CYP24A1

    Interaction Score: 4.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29160302 29099735


    Sources:
    PharmGKB

  • DEFERASIROX   CYP27B1

    Interaction Score: 4.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30651574


    Sources:
    PharmGKB

  • DEFERASIROX   UGT1A3

    Interaction Score: 2.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30651574 28346059 27193993 27043265


    Sources:
    PharmGKB

  • DEFERASIROX   GC

    Interaction Score: 1.77

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30651574


    Sources:
    PharmGKB

  • DEFERASIROX   CYP1A1

    Interaction Score: 0.88

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27193993 25348619


    Sources:
    PharmGKB

  • DEFERASIROX   ABCG2

    Interaction Score: 0.4

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28346059 27193993 27043265


    Sources:
    PharmGKB

  • DEFERASIROX   ABCC2

    Interaction Score: 0.35

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26403473 25348619


    Sources:
    PharmGKB

  • DEFERASIROX   CYP1A2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27193993 25348619


    Sources:
    PharmGKB

  • DEFERASIROX   VDR

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30651574


    Sources:
    PharmGKB

  • DEFERASIROX   AR

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PharmGKB: deferasirox

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Cusato J et al., 2015, Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness., Pharmacogenomics J
    Marano M et al., 2016, Deferasirox-induced serious adverse reaction in a pediatric patient: pharmacokinetic and pharmacogenetic analysis., Eur J Clin Pharmacol
    Allegra S et al., 2019, The effect of vitamin D pathway genes and deferasirox pharmacogenetics on liver iron in thalassaemia major patients., Pharmacogenomics J

  • DTC: DEFERASIROX

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL550348 ChEMBL Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL550348

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21